ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO876

Long-Term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Contreras, Gabriel, University of Miami Health System, Miami, Florida, United States
  • Baker, Matthew G., Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
  • Hodge, Lucy S., Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
  • Yap, Ernie, Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
Background

Black patients with lupus nephritis (LN) are reported to have more severe disease, are often refractory to treatment, and have worse long-term outcomes. Voclosporin in conjunction with low-dose glucocorticoids and mycophenolate mofetil (MMF) has shown significant benefit across ancestries and classes of LN. Here we report outcomes on up to three years of follow-up in patients identifying as Black and treated with voclosporin during the global Phase 3 AURORA studies.

Methods

Key inclusion criteria for the parent AURORA 1 study included biopsy-proven LN, urine protein creatinine ratio (UPCR) ≥1.5 g/g (≥2 g/g for Class V) and estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m2. Patients completing AURORA 1 were eligible to enter the AURORA 2 continuation study on the same blinded therapy of voclosporin or placebo in combination with MMF and glucocorticoids for an additional two years. Programmed complete renal response (CRR; UPCR ≤0.5 g/g, stable eGFR, low-dose steroids, and no rescue medication), partial renal response (PRR; reduction in UPCR of ≥50% from baseline) and safety were assessed in patients self-identifying as Black or mixed Black.

Results

Twenty-six of 179 (14.5%) and 19 of 178 (10.6%) patients identified as Black or mixed Black in the voclosporin and control arms of AURORA 1. Baseline characteristics were similar between arms. CRR rates at one year numerically favored voclosporin (46.2% vs 15.8%, OR 3.92 [CI 0.95, >9.99] p=0.0597) as did PRR rates (69.2% vs 47.4%, OR 2.62 [CI 0.72, 9.45] p=0.1422).

Eighteen voclosporin-treated patients and seven control-treated patients in the Black subgroup continued into AURORA 2. Response rates at three years continued to numerically favor voclosporin (CRR, 44.4% vs. 14.3%, OR 4.17 [CI 0.41, >9.99] p=0.2276; PRR, 66.7% vs. 42.9%; OR 1.67 [CI 0.23, >9.99] p=0.6094). Greater reductions in mean UPCR were observed over the three-year period in the voclosporin arm (change from baseline -3.4 vs -1.5 g/g, p=0.0349). Mean eGFR levels remained stable and in the normal range over three years of treatment.

Conclusion

Black patients treated with a voclosporin-based regimen achieved higher rates of renal response than patients treated with MMF and glucocorticoids alone. For patients entering the continuation study, the response was largely durable for up to 3 years.

Funding

  • Commercial Support – Aurinia Pharmaceuticals Inc.